        item: #1 of 36
          id: cord-006192-bqwchhwk
      author: Persson, Carl G. A.
       title: Plasma exudation and asthma
        date: 1988
       words: 7211
      flesch: 31
     summary: The microcirculation of the tracheal mucosa The role of some higher peptides in inflammation The inflammatory response A study of plasma proteins in the sol phase of sputum from patients with chronic bronchitis Bradykinin and prostaglandin Ex, E2 and F2-induced macromolecular leakage in the hamster cheek pouch The effects of intermittent and continuous stimulation of microvessels in the cheek pouch of hamsters with histamine and bradykinin on the development of venular leaky sites Mechanism of ionophore A23187 induction of plasma protein leakage and of its inhibition by indomethacin Chronic obstructive lung disease. However, the tracheobronchial venular endothelium, which regulates airway inflammatory plasma leakage, has not been considered an important effector cell of the lung.
    keywords: airway; asthma; asthmatic; bronchial; cells; edema; effects; endothelial; inflammatory; leakage; mediators; permeability; plasma; proteins; vascular
       cache: cord-006192-bqwchhwk.txt
  plain text: cord-006192-bqwchhwk.txt

        item: #2 of 36
          id: cord-006860-a3b8hyyr
      author: None
       title: 40th Annual Meeting of the GTH (Gesellschaft für Thrombose- und Hämostaseforschung)
        date: 1996
       words: 90772
      flesch: 46
     summary: The data show that children with low risk did in part receive higher doses of heparin and/or AT III concentrate than did high risk patients, whereas plasma therapy was adjusted to severity of eoagnlopathy. Inhibitor testing was done on patients plasma samples using the Bethesda method.
    keywords: activation; activity; acute; addition; age; agents; aggregation; analysis; antibodies; anticoagulant; anticoagulation; antigen; antithrombin; apc; aptt; assay; binding; bleeding; blood; blood coagulation; blood samples; cases; cells; children; clinical; clotting; coagulation; coagulation factor; complex; complications; concentrations; conclusion; contrast; control; coronary; correlation; count; data; day; days; deficiency; diagnosis; disease; dose; effect; elevated; endothelial; events; expression; factor; factor v; factor viii; family; fibrin; fibrinogen; formation; group; heparin; hirudin; hours; human; incidence; increase; influence; infusion; inhibitor; inr; laboratory; levels; low; mean; median; method; months; mutation; normal; order; parameters; patients; period; phase; plasma; plasma samples; plasminogen; platelet; platelet activation; platelet factor; present; products; protein; protein c; prothrombin; pts; range; reagent; receptor; reduced; release; resistance; response; results; risk; risk factor; role; samples; specific; studies; study; surface; surgery; system; test; therapy; thrombin; thrombosis; time; tissue; total; treatment; type; use; values; vascular; vein; venous; viii; vwf; weight; years
       cache: cord-006860-a3b8hyyr.txt
  plain text: cord-006860-a3b8hyyr.txt

        item: #3 of 36
          id: cord-010328-uxpedpz8
      author: Ciencewicki, Jonathan M.
       title: Plasma Donors in the Southwestern United States Positively Contribute to the Diverse Therapeutic Antibody Profile of Immune Globulin Products
        date: 2020-04-22
       words: 4564
      flesch: 46
     summary: A broad range of anti-HAV Ig plasma titers was observed among these centers, with some centers exhibiting 3–5 times the titers of the others. titers were due to one or a few donors in a given pooled sample or due to an overall higher prevalence in the population, samples from the individual donations comprising twelve of the plasma pools were tested for anti-HAV Ig titers.
    keywords: centers; hav; mev; plasma; pools; products; titers; virus
       cache: cord-010328-uxpedpz8.txt
  plain text: cord-010328-uxpedpz8.txt

        item: #4 of 36
          id: cord-018142-xt71w4nr
      author: Samy Modeliar, S.
       title: Thrombotic Microangiopathy Syndrome in the ICU
        date: 2006
       words: 5064
      flesch: 41
     summary: Plasma exchange therapy achieves complete remission in the majority of these patients [41, 42] . However, until these innovative treatments become available, early diagnosis of these diseases is essential in order to rapidly initiate specific treatment, as the interval between diagnosis and initiation of plasma exchange is a decisive element in the prognosis of TTP.
    keywords: cases; exchange; failure; hus; patients; plasma; syndrome; thrombocytopenic; tma; treatment; ttp
       cache: cord-018142-xt71w4nr.txt
  plain text: cord-018142-xt71w4nr.txt

        item: #5 of 36
          id: cord-018492-d34tyar7
      author: Zaza, Mouayyad
       title: Dried Plasma
        date: 2019-05-06
       words: 7368
      flesch: 45
     summary: Plasma transfusion is an essential part of this approach and remains a significant logistical challenge even today, hence the need for a reliable, shelf-stable, easy-to-carry and administer plasma product such as dried plasma. Recent studies show many beneficial effects of dried plasma in the treatment of shock in large animal models.
    keywords: blood; coagulopathy; ffp; injury; model; patients; plasma; product; resuscitation; shock; transfusion; trauma; treatment; use
       cache: cord-018492-d34tyar7.txt
  plain text: cord-018492-d34tyar7.txt

        item: #6 of 36
          id: cord-018845-r88bhiac
      author: Sachs, U. J. H.
       title: Gewinnung, Herstellung und Lagerung von Blut und Blutkomponenten
        date: 2010-11-21
       words: 8657
      flesch: 43
     summary: Die Richtlinien der AABB Die Gesamtdauer der Vollblutspende soll 15 min nicht überschreiten, um das Risiko einer Gerinnselbildung im Schlauchsystem, das frei von Antikoagulanzien ist, zu vermeiden.
    keywords: als; anwendung; apherese; auch; auf; aus; bei; bis; blood; blut; blutkomponenten; blutspende; bzw; cell; concentrates; das; dass; dem; der; des; die; diese; durch; eine; erythrozyten; für; gewinnung; haben; ist; kann; können; lagerung; mit; muss; müssen; nach; neben; nicht; nur; oder; plasma; platelet; red; regel; richtlinien; sein; sich; sie; sind; soll; sollte; sowie; spender; storage; thrombozyten; transfusion; und; unter; vollblut; von; vor; werden; wird; wurde; während; zur; über
       cache: cord-018845-r88bhiac.txt
  plain text: cord-018845-r88bhiac.txt

        item: #7 of 36
          id: cord-031907-ilhr3iu5
      author: None
       title: ISEV2020 Abstract Book
        date: 2020-07-15
       words: 201435
      flesch: 40
     summary: Normal pancreas cells (hTERT-HPNE and HPDE-H6c7) were co-cultured with cancer cell EVs for 24-48 hours. Before EV isolation cells were kept for 24 h either under normoxia or hypoxia (1% oxygen).
    keywords: ability; activation; activity; ad evs; addition; aim; analysis; analysis methods; anti; approach; assay; associated; bacterial evs; biological; biomarkers; blood; blood cells; blood evs; blot; bone; brain; breast; breast cancer; cancer cells; cancer evs; cancer introduction; cancer patients; cd63; cd81; cd9; cell communication; cell culture; cell evs; cell exosomes; cell function; cell lines; cell proliferation; cell surface; cell types; cells; cells introduction; changes; characterization; chromatography; composition; concentration; conclusion; conditions; content; control; control evs; cultured; current; cytometry; data; delivery; density; detection; development; diagnosis; differential; disease; distribution; dna; drug; effect; electron; endothelial; enrichment; epithelial; ev analysis; ev cargo; ev evs; ev isolation; ev markers; ev numbers; ev preparations; ev production; ev protein; ev release; ev research; ev rna; ev samples; ev subpopulations; ev surface; ev treatment; ev uptake; evs; exclusion; exosomal; exosomes; experiments; expression; expression analysis; extracellular; factors; findings; flow; fluorescent; fluorescent evs; fold; formation; fractions; free; function; funding; gene; group; growth; host cells; human; human evs; imaging; immune; increase; inflammation; inflammatory; introduction; isolated; isolation methods; key; large; levels; lipid; lung; macrophages; mass; mechanisms; media; medium; membrane; membrane vesicles; mesenchymal; metastasis; methods; mice; microscopy; migration; milk evs; mirna; model; molecular; molecules; mouse; msc evs; mscs; nanoparticle; national; neuronal; neurons; new; non; normal; novel; nta; number; particles; pathway; patients; plasma evs; plasma samples; platelet; platform; play; positive; positive evs; post; potential; presence; present; primary; process; production; profile; profiling; progression; proliferation; properties; prostate; prostate cancer; protein; protein cargo; protein expression; protein markers; proteomic; purification; purity; range; recipient cells; research; resistance; response; results; rna; rnas; role; samples; sec; secretion; sequencing; serum; sevs; signalling; single; size; small evs; specific; specific evs; spectrometry; stem cells; stromal cells; studies; study; summary; surface; system; target cells; targets; tau; techniques; tested; therapeutic; therapy; time; tissue; total; total evs; tracking; transfer; transmission; treatment; tumour cells; ultracentrifugation; university; uptake; urinary evs; urine; usa; usa introduction; use; vesicles; vesicles introduction; vitro; vivo; work
       cache: cord-031907-ilhr3iu5.txt
  plain text: cord-031907-ilhr3iu5.txt

        item: #8 of 36
          id: cord-261653-0vtghtp7
      author: Andersen, Kylie J.
       title: Recruitment Strategy for Potential COVID-19 Convalescent Plasma Donors
        date: 2020-09-21
       words: 1668
      flesch: 36
     summary: Rochester, Minnesota required a strategy to interface with the community of recovering COVID-19 patients and recruit eligible convalescent plasma donors. This strategy may be adopted by other institutions to rapidly increase convalescent plasma donor recruitment.
    keywords: blood; convalescent; covid-19; donor; patients; plasma
       cache: cord-261653-0vtghtp7.txt
  plain text: cord-261653-0vtghtp7.txt

        item: #9 of 36
          id: cord-262776-6k7tcgfs
      author: Burnouf, Thierry
       title: Assessment of the viral safety of antivenoms fractionated from equine plasma
        date: 2004-09-30
       words: 8214
      flesch: 39
     summary: For instance, equipment for bulk in process virus inactivation, such as the acid pH incubation or the caprylic acid treatment, should ideally be fully enclosed. The duration of the first stage should be such that the majority of virus inactivation (as found during the viral validation studies) has occurred.
    keywords: acid; antivenoms; blood; disease; enveloped; equine; horses; human; igg; inactivation; manufacturing; plasma; production; products; safety; treatment; virus; viruses
       cache: cord-262776-6k7tcgfs.txt
  plain text: cord-262776-6k7tcgfs.txt

        item: #10 of 36
          id: cord-266147-s8rxzm0t
      author: Burnouf, Thierry
       title: Modern Plasma Fractionation
        date: 2007-03-28
       words: 8837
      flesch: 35
     summary: An updated list of the major therapeutic applications of plasma protein products can be found elsewhere. Modern plasma product production technology remains largely based on the ethanol fractionation process, but much has evolved in the last few years to improve product purity, to enhance the recovery of immunoglobulin G, and to isolate new plasma proteins, such as α1-protease inhibitor, von Willebrand factor, and protein C. Because of the human origin of the starting material and the pooling of 10 000 to 50 000 donations required for industrial processing, the major risk associated to plasma products is the transmission of blood-borne infectious agents.
    keywords: blood; chromatography; factor; fractionation; fviii; heat; igg; inactivation; plasma; process; production; products; protein; removal; safety; steps; treatment; viruses
       cache: cord-266147-s8rxzm0t.txt
  plain text: cord-266147-s8rxzm0t.txt

        item: #11 of 36
          id: cord-270908-9snyt2n1
      author: PERSSON, C. G. A.
       title: Airway permeability
        date: 2006-04-27
       words: 5159
      flesch: 38
     summary: The rate of absorption of ragweed pollen material from the nose Comparative nasal absorption of allergens in atopic and nonatopic subjects Ultrastruktur der allergischen Nasenschleimhaut des Menschen Macromolecular permeability of the tight junction of the human nasal mucosa Role of epithelium Changes in permeability of dog tracheal epithelium in response to hydrostatic pressure Stimulated eosinophils and proteinases augment the transepithelial flux of albumin in bovine bronchial mucosa Oxidants alTect permeability and repair of the cultured human tracheal epithelium Effect of seasonal allergic rhinitis on airway mucosal absorption of Chromiun-51-labelled EDTA The use of the nose to study the inflammatory response of the respiratory tract Airway epithelium and microcirculation Appearance of airway absorption and exudation tracers in guinea-pig tracheobronchial lymph nodes The 'nasal pool' device applies controlled concentrations of solutes on human nasal airway mucosa and samples its surface exudations/secretions Plasma exudation in the airways: mechanisms and function The ultrastructural route of fluid transport in rabbit gall bladder Volume flows across gallbladder epithelium induced by small hydrostatic and osmotic gradients Mechanisms of glucagon-induced intestinal secretion Epithelial pathways for luminal entry of bulk plasma Plasma exudation, epithelial integrity and mucosal absorption ability in airways challenged with PAF and H2O2 Bronchotracheal response in human influenza Effect of polymers and microspheres on the nasal absorption of insulin in rats Persson eta\. nasal absorption of ^'Cr-EDTA in smokers and control subjects Airway mucosal exudation of plasma as a measure of subepithelial inflammation Mechanisms of nasal hyper-reactivity Erjefalt 1. If airway absorption of inhaled material is increased this may cause significant adverse effects because subepithelial cells and different airway end-organs will be abnormally exposed to potentially harmful environment agents.
    keywords: absorption; airway; cells; epithelium; exudation; human; mucosa; nasal; plasma; surface; vivo
       cache: cord-270908-9snyt2n1.txt
  plain text: cord-270908-9snyt2n1.txt

        item: #12 of 36
          id: cord-271764-um001ffd
      author: Garraud, Olivier
       title: Passive immunotherapy with convalescent plasma against COVID-19? What about the evidence base and clinical trials?
        date: 2020-06-27
       words: 1307
      flesch: 30
     summary: Possible mechanisms of action Convalescent Plasma Therapy for Covid-19: State of the Art Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma Effectiveness of convalescent plasma therapy in severe COVID-19 patients Testing an Old Therapy Against a New Disease: Convalescent Plasma for COVID-19 Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how? It would be urged that there is a general preparedness plan to evaluate the assets and liabilities of convalescent plasma to treat emergent infections; as a matter of fact, plasma therapy of convalescent plasma has not been thought of in a recent position paper on preparedness plans [25] .
    keywords: convalescent; covid-19; plasma; therapy
       cache: cord-271764-um001ffd.txt
  plain text: cord-271764-um001ffd.txt

        item: #13 of 36
          id: cord-274150-ukdha3ap
      author: Choi, Jun Yong
       title: Convalescent Plasma Therapy for Coronavirus Disease 2019
        date: 2020-09-03
       words: 3166
      flesch: 36
     summary: Because historical experience of the use of convalescent plasma therapy suggests that the neutralizing activity may correlate with the efficacy of convalescent plasma, the measurement of SARS-CoV-2 neutralizing antibody titers should be considered, if available. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis Ebola virus disease: An emerging and re-emerging viral threat West Nile virus neutralization by US plasma-derived immunoglobulin products The convalescent sera option for containing COVID-19 Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection Evaluation of convalescent whole blood for treating Ebola virus disease in Evaluation of convalescent plasma for Ebola virus disease in Guinea Use of convalescent plasma therapy in SARS patients in Hong Kong Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience Convalescent plasma transfusion for the treatment of COVID-19: Systematic review Convalescent plasma in Covid-19: Possible mechanisms of action Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow Effectiveness of convalescent plasma therapy in severe COVID-19 patients Treatment of 5 critically ill patients with COVID-19 with convalescent plasma Treatment with convalescent plasma for critically ill patients with severe acute respiratory syndrome coronavirus 2 infection Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019 Treatment of coronavirus disease 2019 (COVID-19) patients with convalescent plasma Covid-19 plasma task force.
    keywords: convalescent; covid-19; disease; patients; plasma; therapy; treatment
       cache: cord-274150-ukdha3ap.txt
  plain text: cord-274150-ukdha3ap.txt

        item: #14 of 36
          id: cord-277811-j58qvyum
      author: Mehrani, Hossein
       title: Plasma proteomic profile of sulfur mustard exposed lung diseases patients using 2-dimensional gel electrophoresis
        date: 2011-01-07
       words: 4100
      flesch: 48
     summary: Plasma proteins and peptides are from almost every tissue and cell, and their change in quantity and quality is specific not only to the tissue affected by disease, but also to the disease process itself. P50% S75% P75% Figure 1 SDS-PAGE of plasma proteins fractionated with different concentrations (v/v) of ethanol.
    keywords: analysis; controls; disease; ethanol; haptoglobin; lung; patients; plasma; proteins; spots
       cache: cord-277811-j58qvyum.txt
  plain text: cord-277811-j58qvyum.txt

        item: #15 of 36
          id: cord-280221-s6oxq772
      author: Montelongo-Jauregui, Daniel
       title: Convalescent serum therapy for COVID-19: A 19th century remedy for a 21st century disease
        date: 2020-08-12
       words: 2045
      flesch: 36
     summary: Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? Origin and evolution of pathogenic coronaviruses Bat Coronaviruses in China Remdesivir for the Treatment of Covid-19-Preliminary Report The convalescent sera option for containing COVID-19 Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma Effectiveness of convalescent plasma therapy in severe COVID-19 patients Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19 Treatment with convalescent plasma for COVID-19 patients in Wuhan Convalescent serum lines up as first-choice treatment for coronavirus Early Safety Indicators of COVID-19 Convalescent Plasma in 5,000 Patients Ueber das Zustandekommen der Diphtherie-Immunitä t und der Tetanus-Immunitä t bei A pilot study exploring the feasibility of convalescent plasma transfusion to rescue a group of 10 patients with severe disease showed that 1 dose (200 mL) of convalescent plasma with high neutralizing antibody titers was well tolerated, resulted in disappearance of viremia, and improved clinical symptoms in all patients within days of administration [8] .
    keywords: antibodies; convalescent; covid-19; plasma; therapy; treatment
       cache: cord-280221-s6oxq772.txt
  plain text: cord-280221-s6oxq772.txt

        item: #16 of 36
          id: cord-282252-07uzz649
      author: Sahu, Kamal Kant
       title: Convalescent Plasma Therapy: A Passive Therapy for An Aggressive COVID‐19
        date: 2020-05-21
       words: 1366
      flesch: 49
     summary: Update on epidemiology, disease spread and management The convalescent sera option for containing COVID-19 Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients Use of convalescent plasma therapy in SARS patients in Hong Kong Evaluation of convalescent plasma for Ebola virus disease in Guinea Anti-Ebola Virus Antibody Levels in Convalescent Plasma and Viral Load After Plasma Infusion in Patients With Ebola Virus Disease Treatment of 5 Critically Ill Patients with COVID-19 with Convalescent Plasma Effectiveness of convalescent plasma therapy in severe COVID-19 patients Convalescent plasma transfusion for the treatment of COVID-19: Contrarily, the use of convalescent plasma therapy has been found to be of uncertain benefit in the 2013 African Ebola epidemic (6) .
    keywords: convalescent; patients; plasma; therapy
       cache: cord-282252-07uzz649.txt
  plain text: cord-282252-07uzz649.txt

        item: #17 of 36
          id: cord-284208-8fsqgkw5
      author: Zolla, Lello
       title: Proteomics studies reveal important information on small molecule therapeutics: a case study on plasma proteins
        date: 2008-11-07
       words: 6995
      flesch: 30
     summary: HUPO plasma proteome project: challenges and future directions The human proteome organization plasma proteome project pilot phase: reference specimens, technology platform comparisons, and standardized data submissions and analyses Characterization of the human blood plasma proteome Utilizing human blood plasma for proteomic biomarker discovery Oxidation of proteins: basic principles and perspectives for blood proteomics Proteomic analysis of RBC membrane protein degradation during blood storage Composition of the peptide fraction in human blood plasma: database of circulating human peptides Peptide and protein drug delivery to and into tumors: challenges and solutions Effects of genetic engineering on the pharmacokinetics of antibodies Toward a human blood serum proteome: analysis by multidimensional separation coupled with mass spectrometry Multi-component immunoaffinity subtraction chromatography: an innovative step towards a comprehensive survey of the human plasma proteome Differences among techniques for high-abundant protein depletion Immunoaffinity separation of plasma proteins by IgY microbeads: meeting the needs of proteomic sample preparation and analysis Evaluation of multiprotein immunoaffinity subtraction for plasma proteomics and candidate biomarker discovery using mass spectrometry A novel four-dimensional strategy combining protein and peptide separation methods enables detection of low-abundance proteins in human plasma and serum proteomes Two-dimensional separation of human plasma proteins using iterative free-flow electrophoresis The ProteoMiner in the proteomic arena: a non-depleting tool for discovering low-abundance species Prefractionation, enrichment, desalting and depleting of low volume and low abundance proteins and peptides using the MF10 An investigation into the human serum interactome Protein biomarker discovery and validation: the long and uncertain path to clinical utility Proteomics and disease -the challenges for technology and discovery Clinical proteomics: revolutionizing disease detection and patient tailoring therapy Mining the plasma proteome for cancer biomarkers Strategies for plasma proteomic profiling of cancers Proteomics-driven cancer biomarker discovery: looking to the future Dysregulation of retinoid transporters expression in body fluids of schizophrenia patients Comparative plasma proteome analysis of lymphoma-bearing SJL mice Proteomic characterization of inter-alpha inhibitor proteins from human plasma Proteomic strategies for Individualizing therapy of acute myeloid leukemia (AML) Pharmacogenomics and pharmacoproteomics in the evaluation and management of short stature From genomics to proteomics Mass spectrometry-based proteomics Mass spectrometry-based clinical proteomics Calorimetry outside the box: a new window into the plasma proteome The impact of systems approaches on biological problems in drug discovery Identifying pharmacodynamic protein markers of centrally active drugs in humans: a pilot study in a novel clinical model Alpha cell function in health and disease: influence of glucagon-like peptide-1 Technologies and methods for sample pretreatment in efficient proteome and peptidome analysis Quantitative phosphoproteomic analysis of signaling network dynamics Signaling -2000 and beyond Technology insight: pharmacoproteomics for cancerpromises of patient-tailored medicine using protein microarrays High-content single-cell drug screening with phosphospecific flow cytometry Antibody arrays in cancer research Protein chip technology Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front Progress in protein and antibody In the near future, pharmacoproteomics, the use of proteomic technologies in the field of drug discovery and development, and interactomics, the branch of proteomics which is concerned with identifying interactions between proteins, will allow researchers to (i) know the specific protein changes that occur in biological compartments in response to drug administration; (ii) design small novel therapeutic molecules that can have extended half-lives if carried by plasma protein in the blood stream.
    keywords: analysis; biomarkers; blood; cell; development; discovery; disease; drug; human; interactions; interactome; peptides; plasma; proteins; proteome; proteomic
       cache: cord-284208-8fsqgkw5.txt
  plain text: cord-284208-8fsqgkw5.txt

        item: #18 of 36
          id: cord-284582-xwedgllw
      author: Korabecna, M.
       title: Cell-free DNA in plasma as an essential immune system regulator
        date: 2020-10-15
       words: 5719
      flesch: 38
     summary: It controls the transcription of its target genes in different types of immune cells 40 . The normal functions of these cells were downregulated (notch signaling), potential migration was inhibited, and the genes for attractants of immune cells (CXCL8 and CCL24) were overexpressed (Fig. 2b inset and Fig. 3) .
    keywords: activation; analysis; cells; cfdna; dnase; experiments; expression; fig; plasma; protein; samples; system; turbo
       cache: cord-284582-xwedgllw.txt
  plain text: cord-284582-xwedgllw.txt

        item: #19 of 36
          id: cord-294585-dl5v9p50
      author: Klein, H. G.
       title: Pathogen‐reduction methods: advantages and limits
        date: 2009-02-13
       words: 4522
      flesch: 36
     summary: Pathogen-inactivation of components containing red blood cells presents a particularly challenging dilemma. S303 (Helinx), a small molecule designed for pathogeninactivation treatment of red blood cells, is an alkylating agent derived from a quinacrine mustard that belongs to a class of 'frangible anchor linker effectors' (FRALE) compounds.
    keywords: blood; cells; inactivation; light; pathogen; plasma; platelet; riboflavin; transfusion; treatment; ultraviolet; viruses
       cache: cord-294585-dl5v9p50.txt
  plain text: cord-294585-dl5v9p50.txt

        item: #20 of 36
          id: cord-294684-wfsdjs1f
      author: Vesnaver, Elisabeth
       title: Barriers and enablers to source plasma donation by gay, bisexual and other men who have sex with men under revised eligibility criteria: protocol for a multiple stakeholder feasibility study
        date: 2020-11-02
       words: 6764
      flesch: 42
     summary: The implementation of revised eligibility criteria and gbMSM source plasma donation can be described as an intervention designed to support behaviour change in gbMSM. 6 Consistencies and discrepancies between the two Canadian cities and implications for tailoring strategies to support gbMSM source plasma donation in each context.
    keywords: blood; criteria; donation; donor; eligibility; gbmsm; men; plasma; research; source; source plasma; study
       cache: cord-294684-wfsdjs1f.txt
  plain text: cord-294684-wfsdjs1f.txt

        item: #21 of 36
          id: cord-304616-k92fa15l
      author: Izes, Aaron M.
       title: Assay validation and determination of in vitro binding of mefloquine to plasma proteins from clinically normal and FIP-affected cats
        date: 2020-08-05
       words: 4213
      flesch: 44
     summary: A simple, high pressure liquid chromatography assay was developed to detect mefloquine plasma concentrations in feline plasma. In vitro hepatic metabolism of mefloquine using microsomes from cats, dogs and the common brush-tailed possum (Trichosurus vulpecula) Predicting plasma protein binding of drugs: a new approach Drug-protein binding: a critical review of analytical tools Clinical pharmacokinetics of mefloquine Positive predictive value of albumin: globulin ratio for feline infectious peritonitis in a mid-western referral hospital population A high performance liquid chromatographic assay of mefloquine in saliva after a single oral dose in healthy adult Africans Defining limit of detection and limit of quantitation as applied to drug of abuse testing: striving for a consensus International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Prevalence of feline immunodeficiency virus infection in domesticated and feral cats in eastern Australia Risk factors for feline infectious peritonitis in Australian cats pH adjustment of human blood plasma prior to bioanalytical sample preparation Chemistry (cobas) reference intervals In vitro hepatic metabolism of mefloquine using microsomes from cats, dogs and the common brush-tailed possum Clinical application of mefloquine pharmacokinetics in the treatment of P. falciparum malaria In vitro binding of cefovecin to plasma proteins in Australian marsupials and plasma concentrations of cefovecin following single subcutaneous administration to koalas (Phascolarctos cinereus) Species differences in drug plasma protein binding Selective plasma protein binding of antimalarial drugs to α1-acid glycoprotein Plasma protein binding and blood-free concentrations: which studies are needed to develop a drug? Serum protein concentrations in Plasmodium falciparum malaria Critical assessment of the diagnostic value of feline α1-acid glycoprotein for feline infectious peritonitis using the likelihood ratios approach Protein binding of antimicrobials: methods for quantification and for investigation of its impact on bacterial killing Errors in estimating the unbound fraction of drugs due to the volume shift in equilibrium dialysis Clinical pharmacology: plasma protein binding of drugs What is the true clinical significance of plasma protein binding displacement interactions?
    keywords: binding; cats; concentrations; feline; fip; mefloquine; plasma; protein; samples
       cache: cord-304616-k92fa15l.txt
  plain text: cord-304616-k92fa15l.txt

        item: #22 of 36
          id: cord-305074-wz17u4e7
      author: Fernandez, Javier
       title: Plasma Exchange: An Effective Rescue Therapy in Critically Ill Patients With Coronavirus Disease 2019 Infection
        date: 2020-08-24
       words: 2663
      flesch: 40
     summary: COVID-19: Consider cytokine storm syndromes and immunosuppression Chinese Clinical Trial Registry: A Multicenter, Randomized Controlled Trial for the Efficacy and Safety of Tocilizumab in the Treatment of New Coronavirus Pneumonia (COVID-19) Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: Reanalysis of a prior phase III trial The mechanisms of action of plasma exchange Role of plasma exchange, leukocytapheresis, and plasma diafiltration in management of refractory macrophage activation syndrome Use of therapeutic plasma exchange as a rescue therapy in 2009 pH1N1 influenza A-an associated respiratory failure and hemodynamic shock Dysregulation of immune response in patients with COVID-19 in Wuhan, China Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity Human serum albumin, systemic inflammation, and cirrhosis Therapeutic plasma exchange removes endogenous and exogenous inducers of the systemic inflammatory response (pathogen-associated molecular pattern and damage-associated molecular pattern) and proinflammatory mediators (cytokines and reactive oxygen species) that are involved in the pathogenesis of organ failure (8) .
    keywords: days; exchange; failure; icu; patients; plasma
       cache: cord-305074-wz17u4e7.txt
  plain text: cord-305074-wz17u4e7.txt

        item: #23 of 36
          id: cord-305130-vz72ldbo
      author: Keil, Shawn D.
       title: Inactivation of severe acute respiratory syndrome coronavirus 2 in plasma and platelet products using a riboflavin and ultraviolet light‐based photochemical treatment
        date: 2020-05-14
       words: 3462
      flesch: 43
     summary: Silver Spring, MD: OCOD, 2020 31 FDA: Guidance for industry -revised recommendations to reduce the risk of transfusion-transmitted malaria Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors Risk factors for retrovirus and hepatitis virus infections in accepted blood donors Development of a multisystem surveillance database for transfusion-transmitted infections among blood donors in the United States Use of convalescent plasma therapy in two covid-19 patients with acute respiratory distress syndrome in Korea Effectiveness of convalescent plasma therapy in severe COVID-19 patients Treatment of 5 critically ill patients with COVID-19 with convalescent plasma FDA: Recommendations for Investigational COVID-19 Convalescent Plasma. The Mirasol Pathogen Reduction Technology (PRT) System was created to provide an additional layer of safety to blood products by reducing the risk of transfusion transmission of both known and emerging pathogens.
    keywords: blood; coronavirus; plasma; platelet; products; riboflavin; sars; titre; virus
       cache: cord-305130-vz72ldbo.txt
  plain text: cord-305130-vz72ldbo.txt

        item: #24 of 36
          id: cord-319013-oytqcifa
      author: Focosi, Daniele
       title: Convalescent Plasma Therapy for COVID-19: State of the Art
        date: 2020-08-12
       words: 7487
      flesch: 25
     summary: A proof of concept single arm multicenter interventional trial Improved clinical symptoms and mortality on severe/critical COVID-19 patients utilizing convalescent plasma transfusion Convalescent plasma treatment of severe COVID-19: a matched control study Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial Early safety indicators of COVID-19 convalescent plasma in 5,000 patients Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients COVID-19) patients with convalescent plasma Get rid of the bad first: therapeutic plasma exchange with convalescent plasma for severe COVID-19 The successful use of therapeutic plasma exchange for severe COVID-19 acute respiratory distress syndrome with multiple organ failure Efficacy of therapeutic plasma exchange in severe COVID-19 patients Successful treatment of plasma exchange followed by intravenous immunoglobulin in a critically ill patient with 2019 novel coronavirus infection Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19 Global Vaccine Business Unit on the latest on the coronavirus and Takeda Is it time to rethink UK restrictions on blood donation? Hepatitis E virus in blood components: a prevalence and transmission study in southeast England Pork products associated with human infection caused by an emerging phylotype of hepatitis E virus in England and Wales Hepatitis E risks: pigs or blood-that is the question SARS-coronavirus replication in human peripheral monocytes/macrophages Epitopes required for antibody-dependent enhancement of Ebola virus infection Antibodydependent enhancement of Ebola virus infection Influence of Fc␥RIIA and MBL polymorphisms on severe acute respiratory syndrome Immune phenotyping based on neutrophil-tolymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19 Viral kinetics and antibody responses in patients with COVID-19 Global profiling of SARS-CoV-2 specific IgG/IgM responses of convalescents using a proteome microarray Neutralizing antibodies responses to SARS-CoV-2 in COVID-19 inpatients and convalescent patients Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications First infection by all four non-severe acute respiratory syndrome human coronaviruses takes place during childhood Pre-existing and de novo humoral immunity to SARS-CoV-2 in humans Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins Anti-SARS-CoV IgG response in relation to disease severity of severe acute respiratory syndrome The potential danger of suboptimal antibody responses in COVID-19 Symptomatic SARS-CoV-2 infections display specific IgG Fc structures Afucosylated immunoglobulin G responses are a hallmark of enveloped virus infections and show an exacerbated phenotype in COVID-19 Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study Currently available intravenous immunoglobulin (Gamunex © -C and Flebogamma © DIF) contains antibodies reacting against SARS-CoV-2 antigens High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019 ABO blood group and susceptibility to severe acute respiratory syndrome Inhibition of the interaction between the SARS-CoV Spike protein and its cellular receptor by anti-histo-blood group antibodies HIV-1 incorporates ABO histo-blood group antigens that sensitize virions to complementmediated inactivation Harnessing the natural anti-glycan immune response to limit the transmission of enveloped viruses such as SARS-CoV-2 Specific asparagine-linked glycosylation sites are critical for DC-SIGN-and L-SIGN-mediated severe acute respiratory syndrome coronavirus entry Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV) After demonstration that blood group O health care workers were less likely to become infected with SARS-CoV (137), a research group proved that anti-A blood group natural isoagglutinins (which can also be found in CP plasma from blood group O and B donors) inhibit SARS-CoV entry into competent cells (138) .
    keywords: antibodies; antibody; blood; case; convalescent; coronavirus; covid-19; disease; donors; group; patients; plasma; sars; syndrome; therapy; titers; transfusion; treatment
       cache: cord-319013-oytqcifa.txt
  plain text: cord-319013-oytqcifa.txt

        item: #25 of 36
          id: cord-321697-yua3apfi
      author: Crigna, Adriana Torres
       title: Cell-free nucleic acid patterns in disease prediction and monitoring—hype or hope?
        date: 2020-10-29
       words: 10912
      flesch: 32
     summary: In breast tumour studies, many differentially expressed miRNA have been detected in breast cancer patients compared with healthy women. Additionally, 4 upregulated plasma miRNA (miR-148b, miR-376c, miR-409-3p and miR-801) managed to discriminate breast cancer patients from controls [166] .
    keywords: analysis; biomarkers; blood; breast; cancer; cell; cfdna; crc; detection; diabetes; disease; dna; levels; lung; mirna; patients; patterns; plasma; potential; prostate; serum; stress; study; tumour
       cache: cord-321697-yua3apfi.txt
  plain text: cord-321697-yua3apfi.txt

        item: #26 of 36
          id: cord-322714-s0wge7o4
      author: Joyner, Michael J.
       title: Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients
        date: 2020-07-19
       words: 3295
      flesch: 40
     summary: Although thrombotic and thromboembolic events are emerging clinical complications of COVID-19 11, 12, 20 , our data demonstrate a low rate (<1%) of these events within the first seven days after COVID-19 convalescent plasma transfusion. Patients and Methods From April 3 to June 2, 2020, the US FDA Expanded Access Program for COVID-19 convalescent plasma transfused a convenience sample of 20,000 hospitalized patients with COVID-19 convalescent plasma.
    keywords: convalescent; covid-19; data; events; mortality; patients; plasma; transfusion
       cache: cord-322714-s0wge7o4.txt
  plain text: cord-322714-s0wge7o4.txt

        item: #27 of 36
          id: cord-323656-bzefn894
      author: Yoo, Jin-Hong
       title: Convalescent Plasma Therapy for Corona Virus Disease 2019: a Long Way to Go but Worth Trying
        date: 2020-04-06
       words: 856
      flesch: 48
     summary: Drug treatment options for the 2019-new coronavirus (2019-nCoV) Convalescent plasma: new evidence for an old therapeutic tool? Convalescent plasma as a potential therapy for COVID-19 Use of convalescent plasma therapy in two COVID-19 patients with ARDS in Korea Treatment of 5 critically ill patients with COVID-19 with convalescent plasma We need to examine another important problem in plasma treatment.
    keywords: convalescent; plasma; treatment
       cache: cord-323656-bzefn894.txt
  plain text: cord-323656-bzefn894.txt

        item: #28 of 36
          id: cord-324908-ptlpsnfo
      author: Cao, Huiling
       title: Convalescent plasma: possible therapy for novel coronavirus disease 2019
        date: 2020-05-02
       words: 2799
      flesch: 47
     summary: In 1995, a small study reported that eight patients received 150 to 400 mL of convalescent plasma and seven survived, for a case fatality rate of 12.5% in comparison to 80% in patients without convalescent plasma treatment. Convalescent plasma as a potential therapy for COVID-19 Use of convalescent plasma in Ebola virus infection Passive transfer of antibodies protects immunocompetent and immunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication Evaluation of convalescent plasma for Ebola virus disease in Guinea Use of convalescent plasma therapy in SARS patients in Hong Kong Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients A study in scarlet-convalescent plasma for severe influenza The use of hyperimmune serum for severe influenza infections Treatment with convalescent plasma for influenza A (H5N1) infection Characteristics and outcome of mechanically ventilated patients with 2009 H1N1 influenza in Bosnia and Herzegovina and Serbia: impact of newly established multidisciplinary intensive care units Severe H1N1-associated acute respiratory failure in immunocompromised children Anti-Ebola virus antibody levels in convalescent plasma and viral load after plasma infusion in patients with Ebola virus disease The use of Lassa fever convalescent plasma in Nigeria Convalescent whole blood, plasma and serum in the prophylaxis of measles Ribavirin, human convalescent plasma and anti-beta3 integrin antibody inhibit infection by Sin Nombre virus in the deer mouse model Treatment of MERS-CoV: information for clinicians Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks.
    keywords: convalescent; influenza; patients; plasma; therapy; treatment; virus
       cache: cord-324908-ptlpsnfo.txt
  plain text: cord-324908-ptlpsnfo.txt

        item: #29 of 36
          id: cord-326176-n0xo3e53
      author: Patel, Reema T.
       title: Multiple myeloma in 16 cats: a retrospective study
        date: 2008-03-05
       words: 6975
      flesch: 41
     summary: Although not a common disease in cats, plasma cell myeloma should be added to the list of differential diagnoses for an enlarged, mottled, hypoechoic spleen. Focal or multifocal osteolysis was noted in 6 of 12 (50%) cats for which radiographs were available for review; generalized osteopenia was found in 1 (8.3%) cat.
    keywords: bone; cases; cats; cell; criteria; diagnosis; feline; marrow; monoclonal; myeloma; plasma; protein; proteinuria; study
       cache: cord-326176-n0xo3e53.txt
  plain text: cord-326176-n0xo3e53.txt

        item: #30 of 36
          id: cord-328352-l1q4uvxl
      author: Borlongan, Mia C.
       title: The Disillusioned Comfort with COVID-19 and the Potential of Convalescent Plasma and Cell Therapy
        date: 2020-08-25
       words: 3239
      flesch: 33
     summary: The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory metaanalysis Version 2 Treatment with convalescent plasma for COVID-19 patients in Wuhan Effectiveness of convalescent plasma therapy in severe COVID-19 patients Treatment of 5 critically ill patients with COVID-19 with convalescent plasma Effect of convalescent plasma therapy on viral shedding and survival in covid-19 patients Use of Convalescent plasma therapy in two covid-19 patients with acute respiratory distress syndrome in Korea Active therapy with passive immunotherapy may be effective in the fight against Covid-19 Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review SARS-CoV-2 inflammatory syndrome. The still limited evidence but massively accumulating interest in the safety and efficacy of convalescent plasma treatments may provide the basis for compassionate use of these therapies for COVID-19 in the United States.
    keywords: convalescent; convalescent plasma; covid-19; flu; patients; plasma; treatment; virus
       cache: cord-328352-l1q4uvxl.txt
  plain text: cord-328352-l1q4uvxl.txt

        item: #31 of 36
          id: cord-329228-yjvw2ee1
      author: Shikata, N.
       title: Multi-layered network structure of amino acid (AA) metabolism characterized by each essential AA-deficient condition
        date: 2006-10-13
       words: 4405
      flesch: 48
     summary: In the inferred network, we could draw some interesting interrelations between plasma amino acids as follows: 1) Lysine is located at the top control level and has effects on almost all of the other plasma amino acids. Further investigations on the control mechanism of plasma amino acids should uncover the trigger reasons for diseases or propose a new treatment to improve the physiological conditions, however, the control mechanism is so complicated that the investigations have not been succeeded.
    keywords: acid; amino; amino acid; analysis; concentration; network; plasma; threonine; value
       cache: cord-329228-yjvw2ee1.txt
  plain text: cord-329228-yjvw2ee1.txt

        item: #32 of 36
          id: cord-335316-x2t5h5gu
      author: Madariaga, M. L. L.
       title: Clinical predictors of donor antibody titer and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial
        date: 2020-06-23
       words: 4330
      flesch: 40
     summary: The aim of this study was to establish a translational convalescent plasma program to investigate the relationship between clinical and serological parameters in convalescent plasma donors and define the antibody response of convalescent plasma recipients. Despite variability in donor titer, 80% of convalescent plasma recipients showed significant increase in antibody levels post-transfusion.
    keywords: antibody; blood; convalescent; covid-19; patients; plasma; rbd; recipients; spike; titer; transfusion
       cache: cord-335316-x2t5h5gu.txt
  plain text: cord-335316-x2t5h5gu.txt

        item: #33 of 36
          id: cord-336177-p7b7yw28
      author: Selvi, Valeria
       title: Convalescent Plasma: A Challenging Tool to Treat COVID-19 Patients—A Lesson from the Past and New Perspectives
        date: 2020-09-22
       words: 5464
      flesch: 40
     summary: WHO Pandemia WHO Director-General's opening remarks at the media briefing on COVID-19 -11 Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2 Immunoglobulins or convalescent plasma to tackle COVID-19: buying time to save livescurrent situation and perspectives Convalescent plasma as a potential therapy for COVID-19 Blood transfusion during the COVID-19 outbreak A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19 Treatment of COVID-19: old tricks for new challenges The convalescent sera option for containing COVID-19 Passive immunity in prevention and treatment of infectious diseases Convalescent plasma: new evidence for an old therapeutic tool? Points to consider in the preparation and transfusion of COVID-19 convalescent plasma Ebola virus convalescent blood products: where we are now and where we may need to go Evaluation of convalescent whole blood for treating Ebola virus disease in Convalescent plasma in Covid-19: possible mechanisms of action An augmented passive immune therapy to treat fulminant bacterial infections Position paper on use of convalescent plasma, serum or immune globulin concentrates as an element in response to an emerging virus Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome Use of convalescent plasma therapy in SARS patients in Hong Kong Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection Hyperimmune IV immunoglobulin Treatment The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients Efficacy of convalescent plasma in relation to dose of Ebola virus antibodies Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience Risks and side effects of therapy with plasma and plasma fractions Treatment for emerging viruses: convalescent plasma and COVID-19 Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients Recommendations for investigational COVID-19 convalescent plasma-Food and Drug Administration Convalescent plasma is a clutch at straws in COVID-19 management! However, convalescent plasma was demonstrated to be associated with antiviral activity in patients with COVID-19 (convalescent plasma treatment was associated with higher rates of negative SARS-CoV-2 viral PCR results from nasopharyngeal swabs at 24, 48, and 72 hours); a statistically significant improvement was noted for the convalescent plasma treatment group compared to controls in the subgroup of patients without life-threatening COVID-19 (91% improvement in the plasma group compared to 68% in the control arm).
    keywords: blood; convalescent; convalescent plasma; covid-19; patients; plasma; sars; therapy; treatment; use
       cache: cord-336177-p7b7yw28.txt
  plain text: cord-336177-p7b7yw28.txt

        item: #34 of 36
          id: cord-349031-tbof9yqi
      author: Chen, Shiu-Jau
       title: Novel Antiviral Strategies in the Treatment of COVID-19: A Review
        date: 2020-08-20
       words: 5473
      flesch: 38
     summary: Nord experience Clinical trials on drug repositioning for COVID-19 treatment COVID-19 pandemic: An overview of epidemiology, parthenogenesis, diagnostics and potential vaccines and therapeutics Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment Convalescent plasma in Covid-19: Possible mechanisms of action Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma Effectiveness of convalescent plasma therapy in severe COVID-19 patients Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19 Treatment with convalescent plasma for COVID-19 patients in Wuhan Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea Deployment of convalescent plasma for the prevention and treatment of COVID-19 Convalescent plasma transfusion for the treatment of COVID-19: Systematic review Potential application of the CRISPR/Cas9 system against herpesvirus infections Gene editing technologies and Applications Opioid addiction, genetic susceptibility and medical treatments: A Review Development of CRISPR as an antiviral strategy to combat SARS-CoV-2 and influenza Mesenchymal stem cell therapy for COVID-19: Present or future Current status of cell-based therapies for respiratory virus infections: Applicability to COVID-19 Transplantation of ACE2-Mesenchymal stem cells improve the outcome of patients with COVID-19 pneumonia Expanded umbilical cord mesenchymal stem cells (UC-MSCs) as a therapeutic strategy in managing critically Ill COVID-19 patients: The case for compassionate use Convalescent plasma therapy for persistent hepatitis E virus infection Convalescent plasma new evidence for an old therapeutic tool Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia Use of convalescent plasma in Ebola virus infection Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital Use of convalescent plasma therapy in SARS patients in Hong Kong Convalescent plasma as a potential therapy for COVID-19 Collecting and evaluating convalescent plasma for COVID-19 treatment: In this review, we explore the applications, possible mechanisms, and efficacy in successful cases using convalescent plasma, CRISPR, and MSC therapy for COVID-19 treatment, respectively.
    keywords: cells; convalescent; convalescent plasma; covid-19; disease; efficacy; patients; plasma; sars; therapy; treatment; use
       cache: cord-349031-tbof9yqi.txt
  plain text: cord-349031-tbof9yqi.txt

        item: #35 of 36
          id: cord-351328-ly72scru
      author: Epstein, Jay
       title: Points to consider in the preparation and transfusion of COVID‐19 convalescent plasma
        date: 2020-05-14
       words: 778
      flesch: 30
     summary: key: cord-351328-ly72scru authors: Epstein, Jay; Burnouf, Thierry title: Points to consider in the preparation and transfusion of COVID‐19 convalescent plasma date: 2020-05-14 journal: Vox Sang DOI: 10.1111/vox.12939 sha: doc_id: 351328 cord_uid: ly72scru This document prepared and endorsed by the Working Party on Global Blood Safety of the International Society of Blood Transfusion presents elements, as of April 2020, to take into consideration in the preparation and transfusion of COVID-19 convalescent plasma as a possible treatment approach of COVID-19. This document provides the perspective as of April 2020 of the Working Party on Global Blood Safety of the International Society of Blood Transfusion on use of COVID-19 convalescent plasma as an experimental treatment for COVID-19.
    keywords: covid-19; plasma
       cache: cord-351328-ly72scru.txt
  plain text: cord-351328-ly72scru.txt

        item: #36 of 36
          id: cord-352985-5ccrkfsa
      author: Putter, Jeffrey S.
       title: An Update on COVID-19 Infection Control Measures, Plasma-Based Therapeutics, Corticosteroid Pharmacotherapy and Vaccine Research
        date: 2020-09-04
       words: 2138
      flesch: 34
     summary: Transfus Apher Sci DOI: 10.1016/j.transci.2020.102934 sha: doc_id: 352985 cord_uid: 5ccrkfsa This communication provides a compilation on aspects of COVID-19 infection control measures, describes the potential role of therapeutic plasma exchange to reduce fatality rates, addresses precautions concerning dexamethasone pharmacotherapy and updates the current status on the availability of vaccines. The early uses of therapeutic plasma exchange and low molecular weight heparin, for any clinical trial in development is warranted, in order to interdict the intense inflammatory/kinin driven cascade.
    keywords: coronavirus; covid-19; exchange; infection; patients; plasma
       cache: cord-352985-5ccrkfsa.txt
  plain text: cord-352985-5ccrkfsa.txt

